IntroductionSepsis remains a critical issue and a major cause of death among infants in the U.S.(1) and causes approximately 200,000 annual neonatal deaths worldwide (2). Approximately 21% of very low birth weight (VLBW) infants are affected by at least one episode of late onset sepsis (LOS; with positive blood culture after 72 hours of life)(3). There has been some improvement in the incidence of LOS due to infection control measures(4), but LOS continues to disproportionately affect preterm infants and cause significant morbidities including neurologic impairment, prolonged hospitalization, and death(5).Because prompt recognition of infection and initiation of antibiotic therapy decrease sepsis-related morbidity and mortality, clinicians have a low threshold to evaluate for LOS and empirically treat with broad spectrum antibiotics. However, the lack of reliable diagnostic capability for LOS remains an ongoing issue in the neonatal intensive care unit (NICU). Clinical signs of sepsis are mostly nonspecific and detected late, and current laboratory tools are of limited utility. Specifically, the current gold standard for diagnosis of LOS is blood culture, which has delayed results and limited sensitivity in the setting of small specimen volumes and recent antibiotic administration (6). Adjunct markers of infection such as white blood cell count indices (7), C-reactive protein(8), hypoglycemia, and thrombocytopenia are also nonspecific with poor positive predictive value (PPV)(9, 10). Furthermore, there is lack of consensus on the definition of neonatal sepsis amongst providers (11). As a result, antibiotic treatment is overprescribed in the NICU with 56% of VLBW infants treated with antibiotics while only 21% had culture-proven infection in one large study(3). The adverse effects of prolonged antibiotic exposure in preterm infants include antibiotic resistance, fungal infections, necrotizing enterocolitis (NEC), and death (12)(13)(14). The nonspecific clinical presentation of NEC overlaps with that of sepsis. The early localized bowel inflammation, bacterial penetration, and tissue destruction is often difficult to identify until signs of abdominal distension, bloody stool, bowel perforation, or clinical deterioration appear, often accompanied by sepsis(15). Thus, development of more reliable and specific methods to predict and exclude LOS and/or NEC in preterm infants is essential to improve neonatal outcomes.The advantages of automated vital signs monitoring as an objective tool to detect evolving sepsis is being increasingly recognized (16,17). Several studies have suggested that analysis of vital signs patterns can help clinicians evaluate for impending infection or inflammatory response (e.g., sepsis, NEC) prior to obvious deterioration (18)(19)(20)(21). For example, the HeRO monitoring system detects heart rate variability characteristics that change with LOS. The use of HeRO was associated with a reduction in 30 day mortality in VLBW infants (22,23). The RALIS software was the first to incorporate multiple...